Following the rapid vaccination drives across the world last year, the demand for Covid-19 vaccines is declining. However, booster doses targeting new subvariants are expected to drive sales for coronavirus stocks in the days ahead.
Recently, the U.S. Food and Drug Administration (FDA) advised Covid-19 vaccine makers to update their booster shots, scheduled for this fall, to include components that could combat the currently dominant Omicron BA.4 and BA.5 subvariants. Given the uncertainty associated with Covid-19, it is difficult to determine the demand for vaccines in 2023 and the year ahead.
Amid this backdrop, I used the TipRanks Stock Comparison Tool to compare the following coronavirus vaccine makers to pick the stock that could offer a higher upside from current levels.
The post Which Coronavirus Stock Could Fetch Higher Returns? appeared first on InvestorPlace.